Navigation Links
YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial -

MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary endpoint data from its 99 patient, randomized, placebo-controlled, multi-center Phase IIb trial (DLXLEF-AP4) with AeroLEF(TM). AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. YM previously announced that this trial had successfully achieved its primary endpoint, the summed pain intensity difference/pain relief scores (SPRID4) during the 4 hours from the start of the initial dose of study medication (p=0.0194).

Additional Secondary Efficacy and Safety Findings

The treatment phase of the study began in the post-anesthetic care unit (PACU) after completion of surgery when patients reported a pain intensity score (PI) of at least 2 (moderate pain) on a 4-point verbal rating scale (0 (none) to 3 (severe pain)). The clinical trial study period was up to 12 hours and patients were allowed to self-administer AeroLEF(TM) to treat up to two additional pain episodes during the study period. For each pain episode, patients were instructed to continue the self-administration of drug until achievement of one of the following endpoints: achievement of effective analgesia, completion of full dose, or onset of dose-limiting side effects. Patients were allowed rescue medication at any time following initiation of study treatment.

For the first dose administered in the PACU, the percentage of patients reporting a pain intensity (PI) score of less than or equal to 1 (mild pain or no pain) at the end of the dosing period with AeroLEF(TM) was 59%, a statistically significant difference from placebo (27%)
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
3. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
4. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:7/14/2014)... Ala. , July 14, 2014  Patients and ... patients as Express Scripts and other major pharmacy benefit ... The cuts will directly impact millions of patients who ... medical conditions, including persistent pain from cancer, diabetes and ... begin notifying some patients on July 15. ...
(Date:7/14/2014)... , 14 de julio de 2014 /PRNewswire-HISPANIC PR WIRE/ ... que Barry Epling , presidente de la junta ... de la Compañía. El señor Epling es el dueño ... otorgó la licencia de su formulación, sus propiedades intelectuales ... de apoyo financiero. "El señor Gerald ...
(Date:7/14/2014)... CITY , July 14, 2014  Remedy ... software for healthcare delivery and life sciences research, ... National Pancreas Foundation (NPF) to build the first-ever ... including pancreatic cancer and pancreatitis. "The ... the evolutionary change that thoughtful and committed organizations ...
Breaking Medicine Technology:Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4BioAdaptives se prepara para el próximo paso 2BioAdaptives se prepara para el próximo paso 3Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3
(Date:7/14/2014)... brain injury specialists look back on 40 years of the ... scale in research and clinical practice, in a new Personal ... , The Personal View is published on the 40th ... Lancet article*. Since this seminal publication, the Glasgow Coma ... impairment of conscious level, the clinical hallmark of acute brain ...
(Date:7/14/2014)... 2014 A recent study published in the July ... Academy of Child and Adolescent Psychiatry confirms the ... onset criterion for diagnosis of attention-deficit/hyperactivity disorder (ADHD). , ... set at 7 in DSM-IV, has been raised to ... now set at 12, rather than an earlier age, ...
(Date:7/14/2014)... the company Tissuegnostics, the pathologist Lukas Kenner and his ... identify cancer cells in tissue sections and demonstrate the ... provides a precise picture of the disease and leads ... the results of the study, "Two independent pathologists concur ... diagnosis." , "The recently developed software offers, for the ...
(Date:7/14/2014)... and Hauppauge, NY (PRWEB) July 14, 2014 ... (RGONY), with offices in Hicksville and Hauppauge, NY, ... implant) as a long-lasting treatment for diabetic macular ... Allergan, recently obtained an additional FDA-approved indication for ... approved by the FDA in 2009 for treatment ...
(Date:7/14/2014)... There’s an old adage that says first ... Palette say the products offered in their preorder event ... can reserve The Lash Palette for $40,” said Jenelle Paris, ... , Paris explained that the first 1,000 have already been ... She went on to point out that her company is ...
Breaking Medicine News(10 mins):Health News:Scientists developed new technology for the diagnosis of cancer cells 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 3Health News:The Lash Palette Preorder Event Has Officially Begun 2
... , , Improvement ... ROSEMONT, Ill., Aug. 3 A new study published in ... Joint Surgery (JBJS) finds that two years after anterior cervical ... can be expected to have significant improvement in their headache symptoms. , ...
... LOUIS, Aug. 3 Not just for teens anymore--social networking and ... by adults to interact with their friends, families and to gain ... these tools to the list of ways to interact with their ... its members like never before, Anthem Blue Cross and Blue Shield ...
... Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com ... division have reported results on experiments in which ... after traumatic brain injury have been explored. These ... the Hyperbaric Medical Center, School of Medicine, University ...
... The ... Harper, Jason Mraz, G. Love & others , ... Los Angeles, CA (PRWEB) August 3, 2009 -- Domestix, a Beverly Hills based domestic sales ... Thursday, August 6th at the Malibu Cinemas. "Domestix is thrilled to be involved with Jesse,s Story. ...
... PLAINSBORO, N.J., Aug. 3 Pharmacy & Healthcare Communications, LLC ... Pharmacy Times , a monthly journal that reaches the ... as well as its website, www.PharmacyTimes.com , ... custom supplements, including Pharmacy Times Careers ...
... By injecting man-made, microscopic tubes into tumors and heating ... have discovered a way to effectively kill kidney tumors in ... suggests a potential future cancer treatment for humans. The ... of the National Academy of Sciences ). It is the ...
Cached Medicine News:Health News:Neck Surgery for Cervical Spine Disorders Found to Alleviate Associated Headaches 2Health News:Neck Surgery for Cervical Spine Disorders Found to Alleviate Associated Headaches 3Health News:Anthem Blue Cross and Blue Shield in Missouri Harnesses Social Media to Interact with Members 2Health News:Anthem Blue Cross and Blue Shield in Missouri Harnesses Social Media to Interact with Members 3Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 2Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 3Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 4Health News:"Jesse's Story" to Open The 10th Annual Malibu Film Festival 2Health News:"Jesse's Story" to Open The 10th Annual Malibu Film Festival 3Health News:Pharmacy Times Names New Editorial Director 2Health News:Researchers effectively treat tumors with use of nanotubes 2Health News:Researchers effectively treat tumors with use of nanotubes 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: